Evaluation of Neuromuscular ElectroStimulation in Addition to a Physical Activity Program
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: activity sessions.
- Who it may be relevant to
- Registry conditions: Prostate Cancer. Basic parameters: 18 years — 90 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Management of Patients Under Anti-HORMonal Treatment for Prostate Cancer : Evaluation of Neuromuscular ElectroStimulation in Addition to a Physical Activity Program
Overview
The purpose of the study is to measure the muscle strength of the quadriceps 6 months from the start of the intervention, either the maximum load resistance that can be lifted in a single repetition under standardized conditions with the thigh press.
Detailed description
This is a prospective, longitudinal, open, comparative (two arms), randomized, monocentric study, focusing on a therapeutic strategy (muscle strengthening program with or without NeuroMuscular ElectroStimulation).
Patients will be cared for according to a nutritional and sports support program offered routinely in the investigating center, which corresponds to the recommendations for the care of patients with prostate cancer under Androgen Deprivation Therapy.
Interventions
- Other activity sessions
77 activity sessions ; muscle strengthening, testing or unloading
Primary outcome measures
- Quadriceps muscle strength [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Patient treated with pharmacological androgen deprivation therapy for prostate cancer for more than 26 weeks;
- Performance index (WHO): 0 or 1;
- Patient able to understand the information related to the study, to read the information leaflet and having consented to participate in the study;
- Patient benefiting from a social security scheme;
Exclusion criteria
- Weight ≥ 130 kg;
- Vegetarian food;
- Other associated neoplasia;
- Patient having undergone a bilateral orchiectomy;
- Painful bone metastases, or at risk of fracture;
- Anemia (hemoglobin < 10 g/dL);
- Thrombocytopenia (platelets < 50 G/L);
- Renal impairment (creatinine clearance < 60 mL/min, or albuminuria > 30);
- Patient planning to travel more than 4 weeks continuously in the next 52 weeks;
- Absolute contraindication to physical training (e.g. musculoskeletal, cardiovascular or neurological disorders), according to the doctor specializing in the associated medical condition;
- Contraindication to the use of the neuromuscular electrostimulation device or the impedance meter, in particular infectious disease in the acute phase, fungal infection, dermatitis, unbalanced arrhythmia, epilepsy, wearing an active implantable device (pacemaker, heart artificial, prosthesis incorporating an electromagnetic system), open wound;
- Sports activity already supervised by a third party or at an equal or higher level than the bodybuilding/muscle strengthening work recommended in the study;
- Protected adult patient (under guardianship or curatorship, or under a regime of deprivation of liberty);
- Patient participating in another research, or in a period of exclusion from another research.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Supportive care
Study locations
France · 1 center
- Hôpital privé Pays de Savoie — Annemasse
Identifiers
NCT: NCT05745844 · 2022-A00904-39